Company: STAA
Filing Date: 2025-12-16
Form Type: DEFA14A
Source: 0001193125-25-320166
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-12-16
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting Material under §240.14a-12 |

STAAR SURGICAL COMPANY (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 
 14a-6(i)(1) and 0-11                                                           |

On December 16, 2025, STAAR Surgical Company (“STAAR” or the “Company”) issued the following press release: Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction Increased Alcon Merger Price of $30.75 per Share is an Attractive Outcome for STAAR Stockholders LAKE FOREST, Calif. — December 16, 2025 — STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer ®Lenses (EVO ICL ™) for vision correction, today reported that independent industry analysts have recognized the value provided to STAAR stockholders by the Company’s amended merger agreement with Alcon (SIX/NYSE: ALC) and the merits of the Alcon transaction. The Alcon merger agreement, as revised on December 9, 2025, provides that STAAR stockholders will receive $30.75 per share in cash if the transaction with Alcon is consummated, representing a 74% premium to STAAR’s 90-dayVolume Weighed Average Price as of August 4, 2025 and a